Allogeneic Anti-BCMA CAR T Cells Are Superior to Multiple Myeloma-derived CAR T Cells in Preclinical Studies and May Be Combined with Gamma Secretase InhibitorsAna M. Metelo, Reuben Benjamin, Shafqat Inam et al.|Cancer Research Communications|2022Cited by 39
Allogeneic Anti-Bcma CAR-T Cells Show Tumour Specific Killing Against Primary Multiple Myeloma Cells from Different Genomic Sub-GroupsAna M. Metelo, Reuben Benjamin, Ieuan Walker et al.|Blood|2019Cited by 3
Comparing clinical trial data against a real world dataset – progression-free survival on Len/Dex and Bor/Dex following 1-3 prior lines of treatmentJ. Waters, Matthew Streetly, Reuben Benjamin et al.|Clinical Lymphoma Myeloma & Leukemia|2019Cited by 1